GeoVax Labs, Inc. has initiated engagement with global health and preparedness organizations to explore potential future procurement of its GEO-MVA vaccine candidate for mpox and smallpox preparedness programs. The company is soliciting interest from international organizations that influence or directly procure vaccines for national stockpiles and outbreak response programs, reflecting growing recognition of the need to diversify supply of Modified Vaccinia Ankara vaccines.
Currently, global supply of MVA vaccines is concentrated with a single commercial manufacturer, creating potential vulnerabilities in global health security. The outreach by GeoVax represents an important transition from development toward commercialization planning, with the GEO-MVA program scheduled to initiate a pivotal Phase 3 study in the second half of 2026. Global preparedness programs for smallpox and mpox vaccines represent a potential multi-billion-dollar procurement market supported by national stockpiles, military preparedness programs, and international health organizations.
The GEO-MVA program has progressed through extensive regulatory dialogue with the European Medicines Agency, culminating in scientific advice supporting an expedited development pathway based on a single immunobridging trial to the licensed MVA vaccine. David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that the EMA's guidance validates both the scientific foundation of GEO-MVA and the growing recognition that expanding global MVA vaccine supply is an important public health priority.
Recent mpox outbreaks have reinforced understanding that mpox is not a single episodic event but rather an evolving infectious disease threat with potential for continued geographic expansion and recurrence. As a result, governments and international health organizations are increasingly emphasizing the need for manufacturing diversification and supply redundancy for vaccines used in outbreak response and biodefense preparedness. In the United States, policymakers and defense stakeholders have increasingly recognized that no domestic manufacturing capability currently exists for MVA vaccines, a gap with implications for both civilian preparedness and military readiness.
GeoVax believes GEO-MVA has the potential to become a strategically important medical countermeasure supporting both global public health preparedness and national biodefense initiatives. The company maintains a global intellectual property portfolio supporting its infectious disease and oncology programs. For more information about the company's broader pipeline, including oncology and COVID-19 vaccine candidates, visit https://www.geovax.com.
The discussions initiated by GeoVax occur amid growing policy dialogue regarding the strategic importance of expanding global MVA vaccine manufacturing capacity. Dodd noted that establishing additional MVA manufacturing capability is increasingly viewed as an important component of global preparedness, with growing interest from public health organizations, governments, and defense stakeholders who recognize the strategic importance of supply diversification.
